Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 - Test2 - elhamkhani - TriplyDB

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

http://www.wikidata.org/entity/Q29622893

about

CD28 co-stimulation down regulates Th17 development Statistical issues in first-in-man studies Lost in Translation (LiT): IUPHAR Review 6 Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples Therapeutic antibodies, vaccines and antibodyomes Role of PD-1 in HIV pathogenesis and as target for therapy Bispecific antibodies for cancer therapy: the light at the end of the tunnel?Immunotoxicity of monoclonal antibodies Preclinical development of monoclonal antibodies: considerations for the use of non-human primates Human T regulatory cell therapy: take a billion or so and call me in the morning Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Antibody-based immunotherapy of solid cancers: progress and possibilities Clinical development methodology for infusion-related reactions with monoclonal antibodies Early implementation of QbD in biopharmaceutical development: a practical example Molecular mechanisms of T cell co-stimulation and co-inhibition The Nuremberg Code subverts human health and safety by requiring animal modeling Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science Immunotherapy in the treatment of non-small cell lung cancer Lost in translation: animal models and clinical trials in cancer treatment CD28 co-stimulation in T-cell homeostasis: a recent perspective Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies Molecular Insights into γδ T Cell Costimulation by an Anti-JAML Antibody Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Aptamers: A New Technological Platform in Cancer Immunotherapy Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis A Dormant Microbial Component in the Development of Preeclampsia Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma Unveiling changes in the landscape of patient populations in cancer early drug development Toxicity and management in CAR T-cell therapy In vitro models of cancer stem cells and clinical applications Emerging Therapies for Rheumatoid Arthritis Advances in Cancer Immunotherapy in Solid Tumors CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date Are BiTEs the "missing link" in cancer therapy?Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

P2860

Q21143804-6F0B9765-6507-4916-B2E4-45358433ADD8 Q23018507-DE948475-BC47-435B-8AE7-D4E651B22007 Q24289150-A484CDC7-3EEE-485C-A0AD-64E903DDFD32 Q24289511-834B02D9-E6C9-4DC9-801E-86FB6DF77CF5 Q24599662-23BEDABF-4F52-453A-A69F-C97EC5C1D50A Q24634293-CD2659F8-E955-47AE-A9C7-8962256F25EA Q24644083-F5C8B23D-3E8F-4A12-9010-72380AC291AD Q24653374-A46523F4-8417-455B-A2B0-9A9C0CC9594E Q24655266-67D575E1-7A56-4FE3-8217-2714294D3661 Q24656069-66D42E93-3F0B-4465-B7E0-289C32516149 Q26744654-E07E2D51-54C3-4922-8D46-788DB0D9C0EB Q26766419-C3D43DE1-6D08-411E-A23D-967752AE2836 Q26783175-914884B9-C42C-455A-928F-A394C8C3A71D Q26796099-FA3C1F1F-504A-48E6-ABB0-5E2FF158D0F3 Q26796542-4FD85404-E79C-47ED-AE2B-6B58D2A9901E Q26798184-981FC992-0C96-49DD-8D46-83174952A14A Q26830466-F0701665-AC12-4CBD-91FB-135A45D2CEA5 Q26864888-621BA689-4D17-4743-B076-B01F4CCD11D6 Q26866469-A66332EF-A6EE-478E-95CF-08FE5E37257E Q26995510-0D90AE9B-4ABC-471C-A715-51F5CF106639 Q27000382-3988F53C-62C3-4BE8-A148-F2E1BAD9DD59 Q27000792-A6229012-016B-443D-8A20-B7A72428BF82 Q27007031-5EEC9D05-8210-4B28-B1EA-07C13491038D Q27011297-2169C311-1C0C-406D-B558-7967DDA0419B Q27301837-377DF183-CC1E-4319-AF1D-8408E03DDDB7 Q27666534-81B7762F-FFE9-4D5F-A522-77C8CB76FAB1 Q27690917-D37BF8FD-D814-42E0-98EA-8B152FA41517 Q28068378-971C7CB4-5C5A-4077-8A26-BA35180AE50F Q28068981-C1FD47C1-8144-4BB6-B445-4206D86503A1 Q28069032-3D420A6F-0901-42E2-A2EA-CBABC8D2E233 Q28069689-FA63FEC9-7190-4306-9903-B277400786EF Q28069864-A43071B7-C62C-4564-92AF-4F975C03C3DA Q28073826-66324A0D-6ECC-463A-AE9A-F54658EB49FD Q28075314-75CB753F-43A7-402E-B6D0-F74B856BF0B6 Q28076101-25D50008-BC50-4D7D-9E17-BBC26A2A2E7F Q28078943-1946A932-E949-432C-B5FA-A4EA8F59D4D0 Q28080113-EC047366-930A-4FAE-8DC5-DA5CE878B016 Q28083296-62B9269E-94F3-4850-8A59-3D64F9DEF843 Q28083907-8EC3D473-DB4F-4FD2-B729-50CEB8960EAF Q28084276-3EA27AE1-E285-46CE-99D1-BA8653C8CCD2

P2860

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

http://www.wikidata.org/entity/Q29622893

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@ast

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@en

type

label

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@ast

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@en

prefLabel

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@ast

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@en

P1433

Q29622893-39318C4E-2F8F-4EF0-9F05-C45667FF1A83

P1476

Q29622893-B903E11A-3DE0-4F48-9346-57771BAF1F82

P2093

Q29622893-1EE248A4-BE9B-4B14-B038-6969D6E5696F

Q29622893-8050B925-7125-4996-99C6-ED4AAD80B505

Q29622893-9956C29D-B156-4595-953F-D4289F4B04D1

Q29622893-9F8B745C-015E-407D-B1C5-E6C31FFDDFEC

Q29622893-A7872601-BFD3-47CD-85EF-625193CE4BF0

Q29622893-BB75899C-04CB-4E55-B676-47E65563A329

Q29622893-F4451AEE-2A3F-4B6F-BA15-C9D85CF96E31

P304

Q29622893-42777B2C-FCE6-4D1E-8FE7-AF90D7F16149

P31

Q29622893-6125E535-5D3D-4B16-BC9D-0D4D9B51C48E

P3181

Q29622893-C62F230B-5F9D-4C5D-8A5F-9C4C811CC901

P356

Q29622893-79B47B8F-0DB3-4592-BAB4-95F357F54362

P407

Q29622893-94E9902D-56E6-487F-BB79-DF47D632D598

P433

Q29622893-249864AF-D126-4FD3-A870-987FD3EFCACA

P478

Q29622893-6C9A26C1-9C72-4D64-B224-C36013F40060

P577

Q29622893-2EBA60C1-809E-4D4D-931A-AB6E1256D138

P5875

Q29622893-0A28C9FE-04EF-4D5F-9D6E-62B0481A0EAC

P698

Q29622893-7A84C1AA-C60C-40E5-861E-E0608044CCB9

P921

Q29622893-05CEE412-084C-4E1C-AAC2-165F69AD8599

Q29622893-A08574F8-DED9-48CB-8967-4C67BC5BEFDA

Q29622893-C3A90DA2-590C-41EE-85A6-F4C8E762AF90

P3181

P356

P1433

The New England Journal of Medicine

P1476

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

@en

P2093

Brett SJ

http://www.w3.org/2001/XMLSchema#string

Brunner MD

http://www.w3.org/2001/XMLSchema#string

Castello-Cortes A

http://www.w3.org/2001/XMLSchema#string

Panoskaltsis N

http://www.w3.org/2001/XMLSchema#string

Perry MR

http://www.w3.org/2001/XMLSchema#string

Suntharalingam G

http://www.w3.org/2001/XMLSchema#string

Ward S

http://www.w3.org/2001/XMLSchema#string

P304

1018-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

42144

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA063842

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6879974

http://www.w3.org/2001/XMLSchema#string

P698

16908486

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial